AR071326A1 - Asociacion de dronedarona con al menos un diuretico, su aplicacion en terapeutica cardiovascular. - Google Patents
Asociacion de dronedarona con al menos un diuretico, su aplicacion en terapeutica cardiovascular.Info
- Publication number
- AR071326A1 AR071326A1 ARP090101316A ARP090101316A AR071326A1 AR 071326 A1 AR071326 A1 AR 071326A1 AR P090101316 A ARP090101316 A AR P090101316A AR P090101316 A ARP090101316 A AR P090101316A AR 071326 A1 AR071326 A1 AR 071326A1
- Authority
- AR
- Argentina
- Prior art keywords
- diuretic
- association
- dronedarona
- dronedarone
- application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Reivindicacion 1: Utilizacion de una asociacion de dronedarona o una de sus sales farmacéuticamente aceptables con al menos un diurético para la preparacion de un medicamento destinado a la prevencion de las hospitalizaciones cardiovasculares y/o de la mortalidad, particularmente la mortalidad cardiovascular, en pacientes que tienen antecedentes de fibrilacion auricular o de aleteo auricular. Reivindicacion 2: Utilizacion de una asociacion de dronedarona o una de sus sales farmacéuticamente aceptables con al menos un diurético para la preparacion de un medicamento destinado a regular el nivel de potasio en la sangre. Reivindicacion 8: Asociacion de dronedarona o una de sus sales farmacéuticamente aceptables con al menos un diurético, con excepcion de furosemida, hidroclorotiazida, metolazona, amilorida, espironolactona y manitol. Reivindicacion 9: Asociacion segun la reivindicacion 8, caracterizada por que dicho al menos un diurético es un diurético no-ahorrador de potasio, con excepcion de furosemida, hidroclorotiazida, metolazona y manitol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0802128A FR2930149B1 (fr) | 2008-04-17 | 2008-04-17 | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
US4599908P | 2008-04-18 | 2008-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071326A1 true AR071326A1 (es) | 2010-06-09 |
Family
ID=39684441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101316A AR071326A1 (es) | 2008-04-17 | 2009-04-15 | Asociacion de dronedarona con al menos un diuretico, su aplicacion en terapeutica cardiovascular. |
Country Status (26)
Country | Link |
---|---|
US (1) | US20110136899A1 (es) |
EP (1) | EP2280700A2 (es) |
JP (1) | JP2011517694A (es) |
KR (1) | KR20110005245A (es) |
CN (1) | CN102065856A (es) |
AR (1) | AR071326A1 (es) |
AU (1) | AU2009241966A1 (es) |
BR (1) | BRPI0910559A2 (es) |
CA (1) | CA2721560A1 (es) |
CL (1) | CL2009000918A1 (es) |
CO (1) | CO6300842A2 (es) |
CR (1) | CR11735A (es) |
DO (1) | DOP2010000308A (es) |
EA (1) | EA201071203A1 (es) |
EC (1) | ECSP10010552A (es) |
FR (1) | FR2930149B1 (es) |
IL (1) | IL208749A0 (es) |
MA (1) | MA32355B1 (es) |
MX (1) | MX2010011401A (es) |
NI (1) | NI201000171A (es) |
PE (1) | PE20091808A1 (es) |
SV (1) | SV2010003702A (es) |
TW (1) | TW200951117A (es) |
UY (1) | UY31772A (es) |
WO (1) | WO2009133310A2 (es) |
ZA (1) | ZA201007390B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2280701A2 (en) | 2008-04-17 | 2011-02-09 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
FR2930150B1 (fr) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868179A (en) * | 1987-04-22 | 1989-09-19 | Cohn Jay N | Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate |
US4988513A (en) * | 1990-01-09 | 1991-01-29 | Monsanto Company | Method of treating hypokalemia |
FR2665444B1 (fr) * | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
FR2735365B1 (fr) * | 1995-06-14 | 1997-09-05 | Sanofi Sa | Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires |
FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
US6083991A (en) * | 1997-06-04 | 2000-07-04 | University Of Florida Research Foundation, Inc. | Anti-arrhythmic composition and methods of treatment |
FR2764800B1 (fr) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
US6411840B1 (en) * | 1999-11-16 | 2002-06-25 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation |
FR2803846B1 (fr) * | 2000-01-17 | 2002-04-05 | Clariant France Sa | 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation |
FR2817864B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese |
FR2817750B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
FR2817865B1 (fr) * | 2000-12-11 | 2005-02-18 | Sanofi Synthelabo | Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese |
EP1347756B1 (en) * | 2000-12-27 | 2006-03-08 | Genzyme Corporation | Controlled release of anti-arrhythmic agents from a biodegradable hydrogel for local application to the heart |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
US20030229007A1 (en) * | 2002-05-30 | 2003-12-11 | Roberto Levi | Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia |
DE10237819A1 (de) * | 2002-08-19 | 2004-03-04 | Bayer Ag | 5-Nitrobenzofurane |
US20050004194A1 (en) * | 2003-05-15 | 2005-01-06 | Graves Kurt Chum | Use of organic compounds |
US20060093673A1 (en) * | 2003-06-27 | 2006-05-04 | Coury Arthur J | Controlled release of anti-arrhythmic agents |
WO2005018635A2 (en) * | 2003-08-07 | 2005-03-03 | Cardiome Pharma Corp. | Ion channel modulating activity i |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
FR2875409B1 (fr) * | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
US20070248564A1 (en) * | 2006-04-25 | 2007-10-25 | Roxane Laboratories, Inc. | Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia |
US20090076137A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched dronedarone |
EP2280701A2 (en) * | 2008-04-17 | 2011-02-09 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
FR2930150B1 (fr) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
EP2133075A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion |
EP2133074A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
EP2153830A1 (en) * | 2008-08-07 | 2010-02-17 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack |
FR2959132A1 (fr) * | 2010-04-22 | 2011-10-28 | Sanofi Aventis | Procedes pour l'evaluation et la reduction des risques |
US20120005128A1 (en) * | 2010-06-29 | 2012-01-05 | Sanofi | Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation |
US8602215B2 (en) * | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
-
2008
- 2008-04-17 FR FR0802128A patent/FR2930149B1/fr not_active Expired - Fee Related
-
2009
- 2009-04-15 PE PE2009000519A patent/PE20091808A1/es not_active Application Discontinuation
- 2009-04-15 AR ARP090101316A patent/AR071326A1/es unknown
- 2009-04-16 CA CA2721560A patent/CA2721560A1/fr not_active Abandoned
- 2009-04-16 EA EA201071203A patent/EA201071203A1/ru unknown
- 2009-04-16 CN CN2009801229250A patent/CN102065856A/zh active Pending
- 2009-04-16 WO PCT/FR2009/000450 patent/WO2009133310A2/fr active Application Filing
- 2009-04-16 CL CL2009000918A patent/CL2009000918A1/es unknown
- 2009-04-16 MX MX2010011401A patent/MX2010011401A/es not_active Application Discontinuation
- 2009-04-16 KR KR1020107023064A patent/KR20110005245A/ko not_active Application Discontinuation
- 2009-04-16 JP JP2011504499A patent/JP2011517694A/ja active Pending
- 2009-04-16 BR BRPI0910559A patent/BRPI0910559A2/pt not_active IP Right Cessation
- 2009-04-16 EP EP09738344A patent/EP2280700A2/fr not_active Withdrawn
- 2009-04-16 AU AU2009241966A patent/AU2009241966A1/en not_active Abandoned
- 2009-04-17 TW TW098112872A patent/TW200951117A/zh unknown
- 2009-04-17 UY UY0001031772A patent/UY31772A/es not_active Application Discontinuation
-
2010
- 2010-10-13 US US12/903,374 patent/US20110136899A1/en not_active Abandoned
- 2010-10-14 SV SV2010003702A patent/SV2010003702A/es unknown
- 2010-10-14 CR CR11735A patent/CR11735A/es not_active Application Discontinuation
- 2010-10-14 IL IL208749A patent/IL208749A0/en unknown
- 2010-10-14 NI NI201000171A patent/NI201000171A/es unknown
- 2010-10-15 DO DO2010000308A patent/DOP2010000308A/es unknown
- 2010-10-15 ZA ZA2010/07390A patent/ZA201007390B/en unknown
- 2010-10-15 EC EC2010010552A patent/ECSP10010552A/es unknown
- 2010-10-15 CO CO10128306A patent/CO6300842A2/es not_active Application Discontinuation
- 2010-11-03 MA MA33318A patent/MA32355B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2011517694A (ja) | 2011-06-16 |
UY31772A (es) | 2009-12-14 |
CN102065856A (zh) | 2011-05-18 |
MX2010011401A (es) | 2011-03-02 |
US20110136899A1 (en) | 2011-06-09 |
CR11735A (es) | 2010-11-22 |
CO6300842A2 (es) | 2011-07-21 |
CA2721560A1 (fr) | 2009-11-05 |
BRPI0910559A2 (pt) | 2015-09-22 |
CL2009000918A1 (es) | 2010-06-11 |
SV2010003702A (es) | 2011-03-04 |
FR2930149B1 (fr) | 2011-02-18 |
DOP2010000308A (es) | 2010-11-30 |
WO2009133310A3 (fr) | 2009-12-23 |
NI201000171A (es) | 2012-01-23 |
MA32355B1 (fr) | 2011-06-01 |
ECSP10010552A (es) | 2010-11-30 |
EP2280700A2 (fr) | 2011-02-09 |
AU2009241966A1 (en) | 2009-11-05 |
FR2930149A1 (fr) | 2009-10-23 |
TW200951117A (en) | 2009-12-16 |
PE20091808A1 (es) | 2009-12-03 |
ZA201007390B (en) | 2012-01-25 |
EA201071203A1 (ru) | 2011-06-30 |
IL208749A0 (en) | 2010-12-30 |
KR20110005245A (ko) | 2011-01-17 |
WO2009133310A2 (fr) | 2009-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR122019024895B8 (pt) | uso de um agente bioativo capaz de aumentar a concentração intracelular de hsp70 | |
CL2013002467A1 (es) | Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular. | |
BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
UY33700A (es) | ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?. | |
UY32497A (es) | "2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso" | |
NI201000172A (es) | Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la hospitalización cardiovascular o de la mortalidad. | |
RS54118B1 (en) | METHOD FOR ATRIAL FIBRATION TREATMENT | |
BR112015020078A2 (pt) | jogo estendido com dispositivo de monitoramento de atividade física | |
AR071326A1 (es) | Asociacion de dronedarona con al menos un diuretico, su aplicacion en terapeutica cardiovascular. | |
CL2007002818A1 (es) | Procedimiento para combatir plagas animales u hongos fitopatogenos; composicion agroquimica para la aplicacion en el suelo que contiene al menos un principio activo agroquimico y un adyuvante; uso del adyuvante para preparar composiciones agroquimica | |
CY1110336T1 (el) | Χρηση της αλλοπουρινολης για τη θεραπεια της παλαμοπελματικης ερυθροδυσαισθησιας | |
AR072951A1 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
CL2010001421A1 (es) | Uso de dronedarona en la preparacion de medicamentos utiles para la prevencion de fibrilacion o aleteo auricular persistentes. | |
NI201000181A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona. | |
BR112015004813A8 (pt) | composição de sabão, método de desinfecção de uma superfície e utilizações de uma composição | |
AR057413A1 (es) | Polvo desintegrable oralmente que comprende cilostazol | |
BRPI0519931A2 (pt) | métodos e composições para reduzir o dano microvascular derivado da isquemia | |
Larraín Sutil et al. | The Role of Rhetoric a Dialogical Approach to Thinking | |
Schwingshackl et al. | Deficiency Of Trek Potassium Channels Promotes Ventilator-Associated Lung Injury | |
AR075912A1 (es) | Uso de clopidogrel con acido acetilsalicilico para la preparacion de un medicamento para usarse en la prevencion de fibrilacion auricular | |
AR110957A1 (es) | Agente terapéutico oral para tiroides | |
Takagi et al. | Development Of Novel Biodegradable Powder For Preventing Postoperative Pleural Adhesion In The Rat Model | |
CR11745A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatina debido a la administracion de dronedarona | |
AR078107A1 (es) | Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca | |
PE20160748A1 (es) | Formacion de costra artificial porosa semipermeable |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |